SCHEMBL23038201

SCHEMBL23038201

O=C(NC(C(=O)O)c1c[nH]cn1)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.50
CTSL P07711 1/20 0.46
CTSS P25774 1/20 0.46
CTRB1 P17538 2/20 0.46
PPARG P37231 1/20 0.43
KYNU Q16719 1/20 0.42
POLB P06746 1/20 0.42
CTSK P43235 2/20 0.42
TACR1 P25103 2/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
ELANE P08246 1/20 0.41
PRTN3 P24158 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10825288 0.81 ATM (0.41) ATMCTSLCTSSCTRB1CTSK
SCHEMBL2177823 0.79 ATM (0.42) ATMCTSLCTSSCTRB1CTSK
SCHEMBL254638 0.79 ITGB3 (0.53) CTSLCTSSCTSKTACR1IDO1
SCHEMBL24795018 0.79 ITGB3 (0.53) CTSLCTSSCTSKTACR1IDO1
SCHEMBL4178755 0.79 ITGB3 (0.53) CTSLCTSSCTSKTACR1IDO1
SCHEMBL5162450 0.78 ALDH1A1 (0.47) CTSLCTSSPOLBCTSK
SCHEMBL31139078 0.77 TRPM8 (0.46) ATMCTSLCTSSPPARGKYNU
SCHEMBL31139080 0.77 CTSL (0.42) ATMCTSLCTSSCTSK
SCHEMBL1362502 0.77 ATM (0.77) ATMCTSLCTSSCTRB1PPARG
SCHEMBL3255533 0.77 ATM (0.77) ATMCTSLCTSSCTRB1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-09-14 US disclosed
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-09-14 US disclosed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US disclosed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US disclosed
US-11066425-B1 Oxo-substituted compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-07-20 US disclosed
US-20210147448-A1 OXO-SUBSTITUTED COMPOUND SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-05-20 US disclosed
EP-3786168-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702431-B2 Oxo-substituted compound CYP51A1, OXA1L, O60361 ATM 2315/4885CTSL 480/4885CTSS 784/4885
US-11066425-B1 Oxo-substituted compound CYP51A1, OXA1L, O60361 ATM 2315/4885CTSL 480/4885CTSS 784/4885
US-20210147448-A1 OXO-SUBSTITUTED COMPOUND CYP51A1, OXA1L, O60361 ATM 2315/4885CTSL 480/4885CTSS 784/4885
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND CYP51A1, OXA1L, O60361 ATM 2315/4885CTSL 480/4885CTSS 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.